Neue Suche | Kongressdetail
mail
Druckansicht
 
 

ALS Drug Development Summit

Evvnt Promotion / evvnt
-
24.05.2022 - 26.05.2022  Hyatt Regency Boston, 1 Avenue de Lafayette, 02111 Boston, USA
Time: 09:00 - 16:30
 
Kongressthemen
Meaningful progress in establishing causative genetic mutations and environmental factors implicated in ALS disease progression and advances in validating emerging biomarkers to evaluate treatment response has meant that the landscape for drug development in ALS is exploding. With exciting new targets, revised inclusion criteria, and opportunities to implement digital biomarkers for remote and sensitive monitoring, we have never been closer to bringing meaningful therapies to patients.
Kongressorganizer (PCO)
Hanson Wade
Anmerkungen
Speakers: Amir Lahav, Head of Digital R and D, Digital Healthcare Innovation, Mitsubishi Tanabe Pharma Holdings America, Andrew Wolff, Senior Vice President, Senior Fellow, Clinical Research and Development, Cytokinetics and more.
 

Anfragen und Anmeldung:

https://go.evvnt.com/1004834-2?pid=4832
Frau Stephanie Nketia
 
Kategorien
Allgemeinmedizin
Sprache
Englisch
Kongressgebühr
USD 2199.0 - USD 4297.0
Veranstalter Kontakt
83 Great Titchfield Street
W1W 6RH London
Großbritannien
 
"GOING INTERNATIONAL fördert den Zugang zu Aus-, Fort- und Weiterbildung, unabhängig von sozialen, geographischen und nationalen Grenzen."

European Health Forum GasteinSwiss Tropical and Public Health InstituteHilfswerk AustriaCentro per la Formazione Permanente e l'Aggiornamento del Personale del Servizio SanitarioCenter of ExcellenceÄrztekammer für WienAlumni Club Medizinische Universität WienÖsterreichische Gesellschaft für Public Health